All News

Brentuximab vedotin plus nivolumab, doxorubicin, and dacarbazine appears to be well tolerated in patients with advanced stage classical Hodgkin lymphoma, according to data from the phase 2 SGN35-027 trial.

New studies and treatment options prove to be effective in treating metastatic CRC, notes Joleen Hubbard, MD.

Patients with NPM1-mutated acute monocytic leukemia who are minimal residual disease negative do not appear to benefit from allogeneic stem cell transplant after chemotherapy induction, even with a FLT3 ITD co-mutation.

Phase 2 results showed that the investigational monoclonal antibody axatilimab elicited encouraging clinical activity and tolerability across dose levels in patients with recurrent or refractory chronic graft-vs-host disease.

Retrospective, real-world results showed that oral decitabine and cedazuridine and standard parenteral hypomethylating agents demonstrated similar levels of comorbidities and disease burden in patients with myelodysplastic syndrome.

Single-agent treatment with odronextamab continued to demonstrate encouraging clinical activity, along with a manageable safety profile, in patients with relapsed/refractory diffuse large B-cell lymphoma.

When used as a minimal residual disease (MRD)–guided treatment approach, ibrutinib (Imbruvica) combined with venetoclax (Venclexta) improved progression-free and overall survival (OS) compared with fludarabine, cyclophosphamide, and rituximab (Rituxan; FCR) in patients with treatment-naive chronic lymphocytic leukemia (CLL), as observed in the phase 3 FLAIR trial.

Treatment outcomes with obecabtagene autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia appear to be better in those with lower leukemia burden at lymphodepletion in the FELIX study.

Auto-HCT results in higher overall survival compared with CAR-T cell therapy in patients with relapsed large B-cell lymphoma while they are in complete response, according to findings from a retrospective study.

Dose reductions and interruptions of navitoclax plus ruxolitinib in the TRANSFORM-1 trial appear to be mostly due to thrombocytopenia, according to Naveen Pemmaraju, MD.

Older patients with hematological malignancies who received Orca-T therapy plus myeloablative chemotherapy have similar relapse-free survival rates compared with younger patients.

No patients with myelodysplastic syndrome have any grade 3 or higher acute graft-versus-host disease following treatment with Orca-T in a phase 1b study.

Treatment with golidocitinib meets the primary endpoint of ORR as well as the secondary endpoints of PFS and safety in the phase 2 JACKPOT8 trial.

Data from the phase 1/2 BRUIN study support continuous BTK pathway inhibition as an important sequencing approach in chronic lymphocytic leukemia or small lymphocytic lymphoma, says Jennifer A. Woyach, MD.

A virtual care platform significantly reduces hospital days for patients who are receiving CAR T-cell therapy, says Tonya Cox, BSN, RN, OCN.

Data from the ZUMA-7 trial shows that age alone should not be a barrier of consideration of administering CAR T-cell therapy to patients with large B-cell lymphoma, says Marie José Kersten, MD.

Treatment with zanubrutinib also appears to improve overall survival compared with ibrutinib among patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma in the phase 3 ALPINE trial.

Treatment with venetoclax appears to be well-tolerated in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, says Nilanjan Ghosh, MD, PhD.

A 70% overall response rate was observed when bridging therapy was added to axi-cel for patients with relapsed/refractory large B-cell lymphoma.

Early phase data found that use of D8 Fab CAR results in increased responses and activity for patients with relapsed/refractory multiple myeloma.

The phase ZUMA-2 trial showed safe and efficacious responses for patients with relapsed/refractory mantle cell lymphoma treated with brexucabtagene autoleucel.

The assessment of health-related quality of life for patients with previously treated multiple myeloma was found to be enhanced in the phase 3 KarMMa-3 trial when patients were treated with idecabtagene vicleucel.

The use of teclistamab in the real-world phase 2 MajesTEC-1 analysis showed similar safety and efficacy for patients with relapsed/refractory multiple myeloma.

Results from the phase 1/2 SAVE trial demonstrated an improved objective response rate when revumenib was added to decitabine/cedazuridine, and venetoclax for patients with relapsed/refractory acute myeloid leukemia.

An AI algorithm was created to distinguish prefibrotic primary myelofibrosis and essential thrombocythemia from each other.

Patients with promyelocytic leukemia saw an improved overall survival and relapse-free survival when treated with an all-oral regimen of arsenic trioxide, all-trans retinoic acid, and ascorbic acid.

Ritu Salani, MD, suggests using the immune system to find treatment options for cervical cancer is the logical course of action.

Combining ribociclib with nonsteroidal aromatase inhibitor treatment also produces relapse-free survival and distant disease-free survival benefits in patients with HR-positive, HER2-negative early-stage breast cancer.

More funding is necessary for additional trials investigating the potential clinical benefit of an alpha-lactalbumin vaccine for patients with high-risk operable triple-negative breast cancer and those at high risk of developing the disease, says G. Thomas Budd, MD.

Treatment with atezolizumab among patients with HER2-positive breast cancer in the phase 3 APTneo Michelangelo trial produces no major tolerability issues, says Luca Gianni, MD.